RDR Challenge
Development of a non-invasive tool for measuring rare disease patient mobility in daily living

INDUSTRY SPONSORS
• Chiesi Farmaceutici S.p.A. (Italy)
  Contact: k.dallaglio@chiesi.com; d.ardigo@chiesi.com
• CSL Behring (Australia)
  Contact: Thomas.Verish@cslbehring.com; Ruediger.Gatermann@cslbehring.com

AIM
To develop a set of coordinated non-invasive tools for measuring rare disease patient general movements distinguishing between voluntary and involuntary movements (e.g. by distributing movement-sensors in patients’ home, on their body, on the wheelchair...)

BACKGROUND AND RATIONALE
• Rare disease patients-families-caregivers face important challenges every single day their life. Although enormous progress has been made by increasing international cooperation in the field of clinical and scientific research as well as by sharing of scientific knowledge about rare diseases, there is still a strong need to harvest disease-related information by monitoring patients’ behavior and their symptoms.
• Mobile health technologies such as wearables, wireless medical sensors, apps are real-time registries that can help in determining rare disease patient best care and guaranteeing a tangible improvement of their quality of life. Despite current technological level, there is a lack of integrated systems for collection of mobility information in free daily leaving distinguishing between spontaneous movements and assisted mobility that can generate data suitable for regulatory-accepted patient relevant outcomes
• Benefits for rare diseases
  The availability of a such a tool has the potential to support the improvement of the quality of life of patients care and clinical outcomes by measuring physiological performance (e.g., movement and vital signs) as well as facilitating the assessment of new drugs benefits. In addition, remote assessment of movements offers a tangible advantage as they can reduce travel to study sites for patients and families and increase patient access to research studies. Accurate daily mobility assessment can also help in interpreting overall patient quality of life especially when associated with additional information (e.g. use of pain killers) and can support the estimation of patient independency.

TIMELINES/MILESTONES AND DELIVERABLES
Stage 1 (M18):
• Prototype finalized (6 months for the state of the art and user requirements analyses; 12 months for software programming and fine tuning in parallel with 12 months for preliminary testing and prototype finalization)
Stage 2 (M30):
• Improved and validated set of tools + CE mark obtained

EXPECTED CONTRIBUTION AND EXPERTISE
SME in the field of mobile health technologies is the perfect target of the call, in particular in the selection and/or adaptation of existing technologies in the field of sensors and in the integration of data. People able to generate software for integration of data are also necessary.
Importantly, since patient involvement in the design and set up of these devices represents an added value to the project, the consortium members should be able to offer expertise and support for facilitating patient involvement in the project.

**TOTAL BUDGET: 575.000 €**

**Contribution from the sponsors**

**In kind**

- **Chiesi**
  - Support the involvement of patients in the project
  - Help in the definition of technical and regulatory requirements
- **CSL Behring**
  - Expertise in clinical data management
  - Expertise in e-clin operations

**Financial**

<table>
<thead>
<tr>
<th>Project Name</th>
<th>Total budget (euros)</th>
<th>N° of industrial partners</th>
<th>Min % cash contribution from industrial partner</th>
<th>Cash contribution Industrial partners included in total budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mobility project</td>
<td>575.000</td>
<td>2</td>
<td>30%</td>
<td>100.000 (Chiesi) + 100.000 (CSL Behring) (53%)</td>
</tr>
</tbody>
</table>